Related by context. All words. (Click for frequent words.) 85 Clinical Antipsychotic Trials 81 Intervention Effectiveness 71 ExTRACT TIMI 69 Carotid Revascularization Endarterectomy vs. 68 phase IIIb 68 Intervention Trial GAIT 68 Aggressive Reduction 68 Intervention Trial 68 Glucosamine Chondroitin Arthritis 68 RE LY 67 VADT 67 EURIDIS 67 STEP BD 67 Controlled Trial 67 CLARITY TIMI 67 multicenter randomized controlled 67 Multicenter 66 Cholesterol Levels SPARCL 66 Edge STudy 66 HCV SPRINT 66 CATIE AD 66 prospective nonrandomized 66 Randomized controlled 66 ACTIVE W 66 Digital Mammographic Imaging 65 randomized multicenter trial 65 NSABP B 65 prospective longitudinal 65 Evaluation WISE 65 AIM HIGH 65 number NCT# ClinicalTrials.gov 65 ARBITER 6 65 PREVENT IV 64 Risk Stratification 64 Sequenced Treatment Alternatives 64 Prospective Randomized Trial 64 Meta Analysis 64 Relapsing Multiple Sclerosis 64 Randomised 64 Subgroup analysis 64 CALERIE 64 multicentre randomized 64 HYVET 64 BOLDER II 64 Randomized Phase 64 PROactive study 64 Refractory Angina 64 ECASS 64 Oral Fingolimod 64 ENESTnd 64 SPARCL 64 Acute Myocardial Infarction 64 SCD HeFT 64 Vertos II 64 placebo controlled clinical 64 ASTEROID 64 multicenter randomized clinical 64 Placebo controlled 64 Lipid Lowering Treatment 64 CURRENT OASIS 7 64 MGd 64 ACCORD Lipid 63 multicentre randomized controlled 63 BRIM3 63 Clinical Outcome 63 ONTARGET 63 LUX Lung 63 Randomized Double blind 63 Prospective Randomized 63 International Verapamil SR 63 NICE SUGAR 63 ROCKET AF 63 RE LY ® 63 AVERROES 63 Preclinical Study 63 Sipuleucel T 63 PFO migraine 63 MADIT 63 BCIRG 63 prospective multicentre 63 antiepileptics 63 landmark ATHENA 63 metaanalysis 63 Multicenter Phase 63 citalopram Celexa 63 ACCOMPLISH 63 Myocardial Infarction Study 63 Pooled Analysis 63 CARE HF 63 Systematic Review 63 Relieve Depression 63 Randomized Evaluation 62 blinded randomized placebo controlled 62 subanalysis 62 BARI 2D 62 Clinical Psychiatry 62 Severe Sepsis 62 Multicenter AIDS 62 CATIE 62 meta regression 62 STRIDE PD 62 Prostate Cancer Prevention 62 Double Blind Placebo 62 STICH trial 62 Randomized Controlled 62 Adenoma Prevention 62 Temsirolimus 62 Antihypertensive 62 Phase III AFFIRM 62 Nesiritide 62 Deforolimus 62 Randomized Controlled Trials 62 multicenter multinational 62 reboxetine 62 HORIZONS AMI 62 Randomized Double Blind 62 Fondaparinux 62 Spine Patient Outcomes 62 Arch Neurol 62 AIR2 Trial 62 Safinamide 62 Trandolapril 62 Stenting Trial CREST 62 MAGE A3 ASCI 62 #F FDG PET 62 fosbretabulin 62 registrational Phase 62 NEVO RES 62 orally inhaled migraine 62 J Clin Oncol 62 multicenter placebo controlled 62 JAK Inhibitor 62 CAMMS# 62 Arch Surg 62 GISSI 62 placebo controlled trials 61 Randomized Controlled Trial 61 APPRAISE 61 substudy 61 Prostate Lung Colorectal 61 Antiviral Therapy 61 randomized multicenter 61 prospective observational 61 #-# Full Text 61 cediranib 61 multicenter randomized placebo controlled 61 EmbraceAC 61 Randomized Phase II 61 ASCEND HF 61 NATRECOR ® 61 Val HeFT 61 Raloxifene Evaluation MORE 61 INSPIRE Trial Phase III 61 CAPRIE 61 Observational Study 61 ACRIN 61 EchoCRT 61 Randomized Study 61 RE LY trial 61 TRITON TIMI 61 II Clinical Trial 61 multicentre prospective 61 double blinded randomized 61 Randomized Clinical Trial 61 J Am Coll 61 Prostate AdenoCarcinoma Treatment 61 Asthma Intervention 61 Prospective Multicenter 61 Treat Parkinson Disease 61 Atorvastatin Evaluation 61 journal Lancet Neurology 61 randomized controlled clinical 61 Acute Ischemic Stroke 61 ACUITY trial 61 Cardiotoxicity 61 Treatment Resistant 61 multicenter prospective 61 CIMZIA TM certolizumab pegol 61 Tanespimycin 61 multicenter Phase II 61 PERISCOPE 61 Study Evaluating 61 PERSEUS 61 CALGB # [002] 61 Screening Trial DMIST 61 Alequel 61 Placebo Controlled Trial 61 Platelet Inhibition 61 recurrent malignant glioma 61 CHAMPION PCI 61 Celecoxib APC trial 61 COPERNICUS 61 #:#-# [031] 61 Endovascular Valve Edge 61 Unstable Angina 61 Phase 2b Study 61 Pegylated Liposomal Doxorubicin 61 Alpha Tocopherol Beta Carotene 61 MADIT II 61 longitudinal cohort study 61 CALGB 61 Phase 2b Clinical Trial 61 Gynecologic Oncology Group 61 Phase IIIb study 60 Heterozygous Familial Hypercholesterolemia 60 nonrandomized 60 Molecular Basis 60 Phase IIb III 60 Aggressive Drug Evaluation 60 HDL Selective Delipidation 60 HF ACTION 60 phase IIa clinical 60 TAXUS VI 60 PLCO 60 Novel Oral 60 Percutaneous Tibial Nerve Stimulation 60 recurrent glioblastoma multiforme 60 See CLINICAL PHARMACOLOGY 60 Clinical Trial Results 60 REALITY Trial 60 prospective observational cohort 60 HCV RESPOND 2 60 Ziprasidone 60 Dietary Modification Trial 60 Diagnostic Criteria 60 Teriflunomide 60 abacavir Ziagen 60 Chronic Heart Failure 60 TMC# C# 60 Hepatocellular Carcinoma 60 Prolongs Survival 60 multicenter phase 60 prospective observational studies 60 randomized controlled multicenter 60 Non Alcoholic Steatohepatitis 60 Phase IIB 60 donepezil Aricept 60 Meta analyzes 60 ORAL Sync 60 journal Neurorehabilitation 60 Predisposition 60 ID NCT# 60 Phase 1a clinical 60 Gastric Cancer 60 Zarnestra 60 Neuroepidemiology 60 #:#-# [023] 60 subgroup analyzes 60 HOPE TOO 60 Completes Patient Enrollment 60 aripiprazole Abilify 60 R roscovitine 60 agomelatine 60 Carotid Endarterectomy 60 Pharmacologic 60 Non inferiority 60 Multicenter Study 60 riociguat 60 PRoFESS 60 Phase IIA 60 retrospective cohort study 60 CHARM Added 60 Severe Asthma 60 multicenter randomized 60 Multiple Ascending Dose 60 Suicidality 60 STRATEGY FOR AN OPEN 60 KRN# 60 pregabalin Lyrica 60 Meets Primary Endpoint 60 immunomodulatory agents 60 Glucosamine chondroitin Arthritis 60 Molecular Cancer 60 AREDS 60 EVEREST II 60 comorbid psychiatric disorders 60 prospective randomized controlled 60 Controlled Study 60 interferon gamma 1b 60 randomized Phase IIb 60 Solid Tumors 60 Multicenter Automatic Defibrillator Implantation 60 dose escalation clinical 60 sorafenib Nexavar 60 Sorafenib HCC Assessment 60 tolerability pharmacokinetics 60 Study AREDS 60 J Clin 60 Screening Trial 60 SWOG 60 journal Psychotherapy 60 placebo controlled randomized 60 Ischemic Stroke 59 Cancer Prevention ATBC 59 carotid artery stenting CAS 59 MEND CABG 59 Initiate Phase 59 Hormone Refractory Prostate Cancer 59 BRIM2 59 relapsed MM 59 Blind Placebo Controlled Trial 59 Multicenter Randomized 59 prospective multicenter 59 LUMINATE 59 Long Lesion 59 Outpatient Setting 59 retrospective cohort 59 Women Ischemia Syndrome 59 trials RCTs 59 Clostridium difficile Infection 59 #:#-#,# CrossRef Medline [002] 59 Postmenopausal Women 59 postmenopausal hormone therapy 59 Pathogenesis 59 Nat Genet 59 ADMIRE HF 59 Hepatotoxicity 59 ILLUSTRATE 59 sertraline Zoloft 59 evaluating mipomersen 59 randomized controlled trials RCTs 59 POISE 59 Arch Intern Med 59 Patients Treated With 59 PARTNER Trial 59 Study ADCS 59 galiximab 59 journal Hepatology 59 confirmatory clinical 59 Phase Ib clinical 59 relapsing remitting MS RRMS 59 Ovarian Cancer Screening 59 GOUT 59 tarenflurbil 59 Fulvestrant 59 Initiates Phase III 59 Combination REOLYSIN R 59 venlafaxine Effexor 59 Placebo Controlled 59 Lu AA# 59 Successfully Completes Phase 59 ziprasidone Geodon 59 Multiethnic Study 59 Initiated Phase 59 journal Ophthalmology 59 #:#-# [029] 59 Systematic Treatment 59 Enzastaurin 59 Trial NLST 59 Clinical Trial Data 59 DIRECT Trial 59 Degarelix 59 Phase III multicenter 59 Neurobiological 59 Multicentre 59 invasive lobular carcinoma 59 AVOREN 59 HALTS 59 pharmacogenetic testing 59 Am J Geriatr 59 atorvastatin Lipitor 59 Aneurysm Repair 59 Glatiramer Acetate 59 Myelodysplastic Syndrome MDS 59 Neurochemistry 59 Major Depressive Disorder 59 #:#-# [024] 59 Xelox 59 CBLC# 59 ABCSG 59 Ovarian PLCO Cancer 59 ASSERT 59 candesartan cilexetil 59 RhuDex 59 DMIST 59 multicentre 59 Chemoprevention 59 TACI Ig 59 paroxetine sertraline 59 Phase III Pivotal 59 Combination Treatment 59 prospective randomized multicenter 59 Chicago Multidisciplinary Symposium 59 Pivotal Trial 59 prospective multicenter randomized 59 ENDEAVOR III 59 Truvada tablets 59 AA Amyloidosis 59 SPIRIT IV 59 ALLHAT 59 unfractionated heparin UFH 59 MEVACOR 59 icatibant 59 Acute Coronary Syndromes 59 Pivotal Phase III 59 SORT OUT III 59 VICTOR E3 59 Pivotal Phase 59 Benign Prostatic Hyperplasia 59 Phase IIIb clinical 59 Angiographic 59 phase IIa 59 Subtypes 59 BR.# 59 Overactive Bladder OAB 59 placebo controlled studies 59 PROactive Study 59 Venous Thromboembolism 59 MERLIN TIMI 59 Bioequivalence 59 Left Ventricular Dysfunction 59 paroxetine Paxil 59 Demonstrates Efficacy 59 FOLOTYN ® 59 ziprasidone 59 Generalized Anxiety Disorder 59 PROVE IT 59 Subgroup Analysis 59 Recurrent Breast Cancer 59 ThermoDox ® clinical 59 retrospective observational 58 phase Ib 58 ADAGIO study 58 #:#-# [035] 58 Neoadjuvant 58 RAVEL 58 Oligonucleotides 58 HIV HCV coinfected 58 quinacrine 58 Heart Failure Trial 58 phase IIb clinical 58 Antiepileptic Drugs 58 Antigen Specific 58 ONCONASE R 58 pivotal bioequivalence 58 RG# ITMN 58 Lancet Oncology journal 58 randomized blinded 58 Bucindolol 58 Inflammatory Bowel Diseases 58 olaparib 58 WHIMS 58 pertuzumab 58 TLK# 58 prospective randomized placebo 58 Sprycel dasatinib 58 Phase Ib Clinical Trial 58 Cardiovascular Risk Reduction 58 Afatinib 58 topiramate Topamax 58 Tolvaptan 58 Pharmacotherapy 58 Pralatrexate 58 Phase III Trial 58 Diabetic Neuropathy 58 Randomized Double Blind Placebo 58 ZACTIMA 58 Phase IIb Clinical Trial 58 #:#-# [006] 58 cerebral microbleeds 58 Eluting 58 HPTN 58 Pharmacokinetic 58 reuptake inhibitor 58 efavirenz EFV 58 Cognitive Impairment 58 Radiation Therapy Oncology 58 RE MODEL 58 Pharmacokinetic Study 58 Statistically Significant 58 journal Pharmacotherapy 58 Haptoglobin 58 meta analyzes 58 Arthritis Rheum 58 Investigational Compound 58 Antitumor Activity 58 Prognostic Significance 58 randomized multicentre 58 Diabetologia 58 Paroxysmal Nocturnal Hemoglobinuria PNH 58 endophenotypes 58 J Clin Endocrinol Metab 58 Scandinavian Simvastatin Survival 58 EXPLORE Xa 58 ZOLINZA 58 Cardiovascular Risk 58 CaPSURE 58 Pemetrexed 58 periprocedural MI 58 RECORD1 58 Phase III placebo controlled 58 journal Neuropsychopharmacology 58 Tocilizumab 58 Bivalirudin 58 Aurora Kinase 58 Therapeutic Targets 58 Metabolic Disease 58 IIa clinical 58 Research www. elsevier.com 58 PKC# 58 BRAF inhibitor 58 mGluR2 NAM 58 multicenter clinical 58 Geodon ziprasidone 58 STICH 58 Phase 2a Clinical Trial 58 PANVAC VF 58 Diabetic Macular Edema 58 Aliskiren 58 Ophena TM 58 novel VDA molecule 58 aldosterone antagonists 58 Carotid Stenting 58 prospectively enrolled 58 Cardiol 58 AVADO 58 Tyrima 58 journal Arteriosclerosis Thrombosis 58 PROSTVAC VF 58 prucalopride 58 Vaccine Immunology 58 GERD migraine headaches 58 placebo controlled Phase III 58 Long Term Efficacy 58 Phase III ThermoDox 58 Phase III Clinical Trial 58 Phase III Clinical Trials 58 lexidronam injection 58 Treatment Outcome 58 Psychosomatic Research 58 Tigecycline 58 HDAC Inhibitor 58 randomized controlled clinical trials 58 journal Urology 58 Coronary Revascularization 58 First Patient Enrolled 58 MADIT CRT 58 Bipolar Disorders 58 assn.org 58 Tipranavir 58 cilostazol 58 epoetin alpha 58 clinicopathological 58 Pharmacogenetic 58 ADVANCE PD 58 Ischemic 58 intracranial stenosis 58 EDEMA3 58 ANN INTERN MED 58 acute mania 58 Infarct 58 identifier NCT# 58 Phase IIIb 58 multicenter study 58 Reduces Mortality 58 GAMMAGARD 58 Renal Cell Carcinoma 58 thalidomide Thalomid 58 Aflibercept 58 randomized crossover 58 Diabetic Foot Ulcer 58 Pegylated Interferon 58 selenium supplementation 58 ToGA 58 Alzheimer Disease Cooperative 58 Genetic Markers 58 #:#-# [028] 58 Stent Restenosis 58 Sapacitabine 58 multicenter trials 58 Comorbidity 58 longitudinal observational study 58 clinicopathologic 58 Metastatic Melanoma 58 Pre Exposure Prophylaxis 58 Biomarker Study 58 prospectively randomized 58 blind randomized controlled 58 Cell Lymphoma 58 RIO Lipids 58 pravastatin Pravachol 58 Systolic Hypertension 58 Neuroprotection 57 immunohistochemical 57 meta analysis pooling 57 PIX# [002] 57 HeFH 57 Mechanistic 57 Phase Ib II 57 conducted retrospective cohort 57 HORIZONS AMI trial 57 davunetide intranasal AL 57 CRLX# 57 Eye Disease 57 Phase #b/#a clinical 57 midstage clinical 57 Thromboembolism 57 BZA CE 57 fluvastatin 57 florbetaben 57 Novel Therapies 57 viral kinetics 57 controlled multicenter 57 Wisconsin Sleep Cohort 57 Clinical Psychopharmacology 57 cisplatin gemcitabine 57 bazedoxifene conjugated estrogens 57 Adjunctive 57 J Am Acad 57 neuropathologic 57 pharmacologic treatments 57 Thrombolysis 57 randomized clinical 57 TAXUS IV 57 VFEND 57 HIVNET 57 SANTE 57 Neurological Diseases 57 UKPDS 57 PreCISe 57 multicenter Phase III 57 newer antipsychotics 57 Bipolar Mania 57 J Natl Cancer Inst 57 Myocardial Infarction 57 EDEMA3 trial 57 Tyrosine Kinase Inhibitor 57 Cannabinoid 57 CYPHER R Sirolimus eluting 57 GSK# [002] 57 DEFER 57 Investigational Drug 57 #:#-#,# [003] 57 BERKELEY CA UroToday.com 57 familial aggregation 57 Adjuvant Chemotherapy 57 Cardiac Resynchronization 57 CYT# potent vascular disrupting 57 Prostate Disease 57 Cardiovascular Outcomes 57 Br J Haematol 57 CLINICAL PHARMACOLOGY 57 BMC Musculoskeletal Disorders 57 generalizability 57 Initiates Phase 2b 57 Celebrex celecoxib 57 dyskinesia PD LID 57 Clinical Evaluation 57 alvespimycin 57 EBUS FNA 57 #:#-# [007] 57 serotonin norepinephrine reuptake inhibitor 57 BMC Psychiatry 57 Hemodialysis Patients 57 secretin 57 CYPHER ® Sirolimus eluting 57 PRE SURGE 57 NESARC 57 #:#-# [020] 57 Raloxifene STAR 57 nondemented 57 Phase III randomized 57 sunitinib Sutent 57 Placebo Controlled Study 57 Acute Decompensated Heart Failure 57 Hodgkin lymphoma HL 57 Pharmacogenetics 57 Cerebral Cortex 57 Surgical Treatment 57 Neuvenge 57 invasive candidiasis 57 Multimeric 57 Overactive Bladder 57 Clinicaltrials.gov 57 Ocular Hypertension Treatment 57 Anticancer Drug 57 antidepressants fluoxetine 57 AEGR 57 CHARISMA 57 Antifungals 57 dyslipidaemia 57 Percutaneous Coronary Intervention 57 ELACYT 57 Initiates Phase II 57 phase IIb study 57 Comparative Effectiveness 57 controlled multicenter Phase 57 Nonalcoholic Fatty Liver Disease 57 Hormone Receptor Positive 57 Molecular Psychiatry 57 Bosutinib 57 Heart Failure Patients 57 Systemic Lupus Erythematosus 57 randomized Phase III 57 rosuvastatin Crestor 57 Septic Shock 57 TORISEL TM 57 Clinical Outcomes Utilizing Revascularization 57 pan HDAC inhibitor 57 Alzheimer disease cognitive impairment 57 Golimumab 57 euthymic patients 57 Clinical Practice Guideline 57 metastatic castration resistant 57 #:#-# [025] 57 Patients Receiving 57 Diabetic Nephropathy 57 Histologic 57 Therapeutic Advances 57 meta analytic 57 Myocardial Ischemia 57 SYNTAX trial 57 Fixed Dose 57 Interferon Beta 57 Bipolar Depression 57 Ann Oncol 57 Randomized Phase III 57 Parathyroid Hormone 57 Dose Escalation 57 ritonavir boosted 57 familial amyloidotic polyneuropathy FAP 57 FOR AN OPEN 57 QLT# 57 Tumor Response 57 genetic polymorphisms 57 polyarticular 57 dual endothelin receptor antagonist 57 neratinib 57 eritoran 57 Juvenile Idiopathic Arthritis 57 Cardiovascular Events 57 p# biomarker 57 complement inhibitor eculizumab 57 Selective Serotonin Re 57 pharmacoeconomic analysis 57 blinded placebo controlled 57 CUSTOM II 57 SPIRIT FIRST 57 Intracranial Aneurysms 57 rEEG 57 Mg Usa 57 CINQUIL 57 Coronary Artery Bypass Graft 57 metastatic malignant 57 Pimavanserin 57 journal Molecular Psychiatry 57 Cloretazine 57 adenoma recurrence 57 ARCOXIA 57 APEX AMI trial 57 Environ Health Perspect 57 Myelofibrosis 57 Comorbidities 57 Chronic Lymphocytic Leukemia 57 Targeted Therapy 57 imipramine Tofranil 57 Adjuvant Treatment 57 meta analysis 57 Patient Outcomes 57 Leukemias 57 mg BID dose 57 neuroleptic 57 HeFT 57 Hypertensive Patients 57 Effective Treatments 57 Preclinical Data 57 pharmacodynamic properties 57 #:#-# [033] 57 Clinical Efficacy 57 multicentre randomized double 57 Symptom Management 57 Advanced Renal Cell 57 #:#-# [001] 57 Complicated Skin 57 pharmacodynamic effects 57 Lung Cancer Screening 57 recurrent glioma 57 Desvenlafaxine 57 relapsing multiple sclerosis 57 Refractory Hodgkin Lymphoma 57 plasma pharmacokinetics 57 Cochrane Database 57 Relieve Depression STAR 57 observational cohort study 57 induce orthostatic hypotension 57 Renal Cell Carcinoma RCC 57 treatment naive genotype 57 Multicenter Randomized Double 57 Motility 57 risperidone Risperdal 57 DHEA supplementation 57 TIMI Study Group 57 Female Sexual Arousal 57 evaluating Actimmune 57 Dual Antiplatelet Therapy 57 Neurotherapeutics 57 STEALTH C 57 Study Demonstrates 56 Immunologic 56 transient elastography 56 Schizophrenia Bulletin 56 TRANSFORMS 56 Metastatic Prostate Cancer 56 anti arrhythmic drug 56 ACCORD Eye 56 Acute Heart Failure 56 Atomoxetine 56 Atopic Dermatitis 56 randomized controlled Phase 56 Dialysis Outcomes 56 Stereotactic Body Radiation Therapy 56 venlafaxine XR 56 #:#-#,# CrossRef Medline [001] 56 Metabolic Efficiency 56 TRA 2P 56 journal Psychological Bulletin 56 NCCTG N# 56 Genetic Variation 56 virus HCV protease inhibitor 56 REMINYL ® 56 Demonstrates Sustained 56 Neuroprotective Effects 56 Relapsing Remitting Multiple Sclerosis 56 Reduce Cardiovascular 56 Antipsychotic 56 Tesmilifene 56 Universal Flu Vaccine 56 Prednisone Against Refractory 56 Histological 56 Phase IIb Trial 56 toenail onychomycosis 56 CALGB # [001] 56 non nucleoside HCV 56 fidaxomicin Phase 56 tocilizumab 56 HuMax EGFr 56 Phase 2b Trial 56 GW# [003] 56 inhibitor RG# 56 blinded randomized controlled 56 beta carotene supplementation 56 RCTs 56 tricyclic antidepressants TCAs 56 neoadjuvant 56 DAPT Study 56 SYNTAX 56 Affective Disorders 56 Pulmonary Arterial Hypertension 56 genomewide association study 56 Multicenter Trial 56 fluoxetine Prozac 56 Clinical Implications 56 Histopathological 56 Unfractionated Heparin 56 CA9 SCAN 56 Early Relapsing Multiple 56 Cerebrovascular Diseases 56 Cardiac Allograft Rejection 56 Endocrine Practice 56 OvaRex ® MAb 56 Lung Cancer Drug 56 Ranolazine 56 Therapeutic Effects 56 phase IIb trial 56 Randomized trials 56 Orthostatic Hypotension 56 ASCO GI 56 B vitamin supplementation 56 Pivotal Clinical Trial 56 Malignant Melanoma 56 #:#-#,# [002] 56 Cloretazine R 56 DAPT 56 J Nutr 56 Paxil paroxetine 56 Randomized Placebo Controlled 56 placebo controlled Phase 56 coinfected patients 56 TAXUS ATLAS 56 #:#-# [019] 56 evaluating tivozanib 56 ISAR REACT 56 iPrEx 56 Phase Ib IIa 56 depsipeptide 56 Pre RELAX AHF 56 Phase #/#a 56 ATTRACT 56 NEJM 56 journal Hormones 56 Stenting Trial 56 Free Full Text 56 Remission Maintenance 56 Psychopharmacology 56 Interpersonal Psychotherapy 56 Schizophrenia Treatment 56 PRECISE 56 ATACAND 56 Initiates Clinical Trial 56 Analytical Tool 56 Cedars Sinai Maxine Dunitz 56 chronic rhinosinusitis CRS 56 Pharmacodynamic 56 coinvestigators 56 ONTARGET R 56 Dr. Kandzari 56 Phase 2b kidney transplant 56 Pirfenidone 56 PD LID 56 Prof. Gozes 56 National Emphysema Treatment 56 acting injectable formulation 56 BOLDER 56 ganaxolone 56 B Cell Lymphoma 56 susceptibility locus 56 ISEL 56 Antiviral Activity 56 Inflammatory Markers 56 PCPT 56 Motesanib 56 elotuzumab 56 General Psychiatry #:#-#,# 56 colorectal liver metastases 56 selective phosphodiesterase 56 Sirolimus eluting Coronary Stent 56 β blockers 56 endothelin antagonists 56 Dr. Relkin 56 Clinical Significance 56 Anti Tumor 56 oral rivaroxaban 56 CNS Disorders 56 Plus Ribavirin 56 depressive episodes associated 56 Toxicogenomics 56 journal Anesthesia 56 tanespimycin 56 Diabetes Complications 56 ENDEAVOR IV 56 prostate cancer CaP 56 Antiplatelet 56 TASKi2 56 Common Toxicity Criteria 56 Teriparatide 56 phase IIb III 56 PRESEPT 56 Cancer Incidence Mortality 56 Bone Metastases 56 glatiramer acetate 56 Paliperidone Palmitate 56 brivaracetam 56 Aortic Stenosis 56 Cytotoxicity 56 Optical Coherence Tomography 56 Mimetics 56 trastuzumab Herceptin ® 56 Eculizumab 56 Invasive Breast Cancer 56 Zeldox 56 intensive lipid lowering 56 Am J Epidemiol 56 donepezil 56 flutamide 56 Bayer HealthCare Onyx Pharmaceuticals 56 ENGAGE AF TIMI 56 Androgen Receptor 56 noscapine 56 Renal Artery 56 Neuropsychologia 56 visilizumab 56 journal Biomacromolecules 56 neuroimaging studies 56 underwent CABG 56 Neuropsychiatric Inventory NPI 56 Anti VEGF 56 Investigational Treatment 56 clomipramine 56 LEVAQUIN ® 56 uricase 56 BRCA testing 56 Azacitidine 56 underwent liver transplantation 56 Suppl. 56 preclinical efficacy 56 Cognitive Function 56 genomewide 56 ENDEAVOR clinical 56 retinal vein occlusion induced 56 methodologic 56 lipid lowering drugs 56 Kaplan Meier analysis 56 Meta Analyses 56 Dendreon Provenge 56 everolimus eluting stents 56 neuroleptics 56 ICON7 56 strontium ranelate 56 AACR San Antonio